Researchers at ETH Zurich have made significant strides in Alzheimer's research by identifying a new target protein, GRK2, which plays a crucial role in the disease's progression. The team, led by Professor Ursula Quitterer, developed an experimental compound known as Compound 10, which effectively blocks the harmful processes associated with GRK2. In studies involving mice, this compound not only reduced nerve cell loss but also improved mitochondrial function and decreased amyloid beta levels, a protein linked to Alzheimer's. Notably, mice treated with Compound 10 exhibited healthier aging, showing fewer gray hairs and improved heart function. The research, which began nearly two decades ago, highlights the complexity of Alzheimer's and the challenges faced in developing effective treatments. The team has filed a patent for Compound 10 and is now looking for a pharmaceutical partner to further its development. This breakthrough could pave the way for new treatment strategies that may enhance the quality of life for Alzheimer's patients by targeting mechanisms not addressed by current medications.